{"id":"NCT04202679","sponsor":"Sanofi","briefTitle":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)","officialTitle":"A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-01-16","primaryCompletion":"2021-08-30","completion":"2021-11-22","firstPosted":"2019-12-17","resultsPosted":"2022-09-28","lastUpdate":"2022-12-21"},"enrollment":160,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Neurodermatitis"],"interventions":[{"type":"DRUG","name":"Dupilumab SAR231893","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Moisturizers","otherNames":[]},{"type":"DRUG","name":"Low to medium potent topical corticosteroids","otherNames":[]},{"type":"DRUG","name":"Topical calcineurin inhibitors","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Dupilumab 300 mg Q2W","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo demonstrate the efficacy of dupilumab on itch response in participants with prurigo nodularis (PN), inadequately controlled on topical prescription therapy or when those therapies are not advisable.\n\nSecondary Objectives:\n\nTo demonstrate the efficacy of dupilumab on additional itch endpoints in participants with PN, inadequately controlled on topical prescription therapy or when those therapies are not advisable.\n\nTo demonstrate efficacy of dupilumab on skin lesions of PN. To demonstrate the improvement in health-related quality of life. To evaluate safety outcome measures. To evaluate immunogenicity of dupilumab.","primaryOutcome":{"measure":"Percentage of Participants With Greater Than or Equal to (>=) 4 Points Improvement (Reduction) From Baseline in Worst-Itch Numeric Rating Scale (WI-NRS) Scores at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Placebo","deltaMin":22,"sd":null},{"arm":"Dupilumab 300 mg Q2W","deltaMin":37.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0216"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":57,"countries":["United States","Canada","Chile","France","Hungary","Italy","Portugal","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["38865146","37142763"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":82},"commonTop":["Headache","Accidental Overdose","Nasopharyngitis"]}}